TACC3 inhibitor 2

TACC3 inhibitor 2 (Compound 13b) potently inhibits the proliferation of JIMT-1 breast cancer cells with high TACC3 expression, with an IC₅₀ of 0.2 μM^[1].
TACC3 inhibitor 2 (10 μM) specifically binds to TACC3 in MDA-MB-231 and MDA-MB-157 triple-negative breast cancer cells, and protects this protein from pronase digestion at a concentration of 10 μM^[1].
TACC3 inhibitor 2 preferentially inhibits the proliferation of MDA-MB-157, HCT-116 and RKO cancer cells with high TACC3 expression, with IC₅₀ values of 0.86 μM, 0.31 μM and 0.20 μM, respectively, while shows weak activity against MCF-7 cells and HT-29 colon cancer cells with low TACC3 expression^[1].
TACC3 inhibitor 2 (0.05-0.5 μM; 12-14 d) reduces the colony-forming ability of MDA-MB-157, HCC38, MDA-MB-231, BT-20 and CT-26 cancer cells in a dose-dependent manner under the treatment condition of 0.05-0.5 μM for 12-14 days^[1].
TACC3 inhibitor 2 (200 nM) induces mitotic arrest, apoptosis and DNA damage in JIMT-1 breast cancer cells, and increases the levels of p-Histone H3 (Ser10), cleaved PARP and p-H2AX (Ser139)^[1].
The metabolic stability of TACC3 inhibitor 2 in human liver microsomes is significantly improved, with a half-life of 78.72 min and an intrinsic clearance rate of 17.7 μL/min/mg^[1].
TACC3 inhibitor 2 shows no significant inhibitory effect on CYP1A2, 2A6, 2B6, 2D6 and 2E1, weak inhibitory effect on CYP2C8, CYP2C9, CYP3A4-M and CYP3A4-T, and moderate inhibitory effect on CYP2C19 (IC₅₀=2.17 μM)^[1].
TACC3 inhibitor 2 exhibits favorable hERG safety profiles, with an IC₅₀ of 17.16 μM for its inhibitory effect on hERG channels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.